Medical Devices · NYSE: BSX
Boston Scientific earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 3 Feb 2027
Latest: Q3 2026
Share loss in electrophysiology and Watchman, worsened by a cyberattack, leads Boston Scientific to call 2027 the trough while it leans on new launches and the pending Penumbra deal.
Two of Boston Scientific's biggest franchises, electrophysiology (EP) and Watchman, are now pulling the company down. EP is losing pulsed field ablation share to newer rival technologies, and Watchman's U.S. standalone procedures fell as physicians reassess the clinical evidence. An August cyber incident halted manufacturing and shipping for about eight business days. Interventional cardiology grew 19% and neuromodulation grew 13%, while urology, endoscopy and China pricing lagged.
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $4.6B * |
| Q1 2025 | $4.7B |
| Q2 2025 | $5.1B |
| Q3 2025 | $5.1B |
| Q4 2025 | $5.3B * |
| Q1 2026 | $5.2B |
| Q2 2026 | $5.4B |
| Q3 2026 | $5.1B |
Data
| Q1 2025 | $0.45 |
| Q2 2025 | $0.53 |
| Q3 2025 | $0.51 |
| Q1 2026 | $0.90 |
| Q2 2026 | $0.61 |
| Q3 2026 | $0.40 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 14.8% |
| Q1 2025 | 19.8% |
| Q2 2025 | 16.2% |
| Q3 2025 | 20.7% |
| Q4 2025 | 15.6% |
| Q1 2026 | 21.2% |
| Q2 2026 | 21.6% |
| Q3 2026 | 16.1% |
Data
| Q4 2024 | $1.2B |
| Q1 2025 | $354.0M |
| Q2 2025 | $1.1B |
| Q3 2025 | $1.2B |
| Q4 2025 | $1.0B |
| Q1 2026 | $171.0M |
| Q2 2026 | $1.3B |
| Q3 2026 | $868.0M |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.6Bd | $4.7B | $5.1B | $5.1B | $5.3Bd | $5.2B | $5.4B | $5.1B |
| Gross margin | 67.9% | 68.8% | 67.7% | 69.9% | 69.6% | 69.5% | 70.7% | 66.7% |
| Operating income | $675.0Md | $921.0M | $819.0M | $1.0B | $825.0Md | $1.1B | $1.2B | $828.0M |
| Operating margin | 14.8% | 19.8% | 16.2% | 20.7% | 15.6% | 21.2% | 21.6% | 16.1% |
| Net income | $562.0Md | $672.0M | $795.0M | $755.0M | $670.0Md | $1.3B | $905.0M | $580.0M |
| Diluted EPS | — | $0.45 | $0.53 | $0.51 | — | $0.90 | $0.61 | $0.40 |
| Operating cash flow | $1.5Bd | $541.0M | $1.3Bd | $1.3Bd | $1.4Bd | $348.0M | $1.5Bd | $1.0Bd |
| Capital expenditure | $277.0Md | $187.0M | $157.0Md | $181.0Md | $351.0Md | $177.0M | $195.0Md | $180.0Md |
| Free cash flow | $1.2B | $354.0M | $1.1B | $1.2B | $1.0B | $171.0M | $1.3B | $868.0M |
| R&D expense | $459.0Md | $443.0M | $526.0M | $514.0M | $569.0Md | $516.0M | $554.0M | $520.0M |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 2 Nov 202610-Q for the period ended 30 Sep 2026SEC ↗
- 3 Aug 202610-Q for the period ended 30 Jun 2026SEC ↗
- 1 May 202610-Q for the period ended 31 Mar 2026SEC ↗
- 17 Feb 202610-K for the period ended 31 Dec 2025SEC ↗
- 3 Nov 202510-Q for the period ended 30 Sep 2025SEC ↗
- 1 Aug 202510-Q for the period ended 30 Jun 2025SEC ↗
- 1 May 202510-Q for the period ended 31 Mar 2025SEC ↗
- 18 Feb 202510-K for the period ended 31 Dec 2024SEC ↗